ArticleTechniques in coloproctology2026
Feasibility and advantages of delivering radiofrequency ablation treatment for haemorrhoids under local anaesthesia in the outpatient setting in the UK: our initial experience.
Article in Techniques in coloproctology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRadiofrequency ablation (RFA) for haemorrhoids has emerged as a minimally invasive treatment for grade II-III haemorrhoids, offering reduced postoperative pain and faster recovery compared with conventional surgery. However, most published data describe the procedure in theatre under general anaesthesia, limiting accessibility and increasing costs.
methodsWe conducted a prospective evaluation of radiofrequency ablation performed under local anaesthesia in an outpatient setting for patients with grade II-III haemorrhoids refractory to conservative therapy for a period of 2 years between 2022 and 2024. Procedures were performed using the RAFAELO
resultsIn total, 53 patients were included in the study with median age of 58 years. A total of 33.9% of patients were ASA 3/4; seven of these patients were on anticoagulants, and their medications were stopped according to the British Society of Gastroenterology (BSG) guidelines. All the patients were able to complete the procedure under local anaesthetic in outpatient setting. All procedures were completed under local anaesthesia with same-day discharge and no major complications. Median follow up was 135 days. At 2-4 months, significant improvement in HSS was observed (mean difference 9.50; 95% CI 5.34-13.66; p < 0.001). The 12-month findings (n = 11) suggested possible persistence of benefit but are limited by substantial attrition and symptom-driven follow-up and should not be generalised. The quality-of-life scores (EQ-VAS) showed a 63% improvement between preoperative and 2-4-month values (p < 0.001). No statistically significant improvement was observed at 12 months within the remits of a small symptom-selected sample (n = 11). In total, six patients (11.3%) required subsequent operative intervention. None of the patients who were on anticoagulants had any bleeding complications or any unplanned return to tertiary care.
conclusionsOur experience demonstrates that radiofrequency ablation treatment for haemorrhoids can be safely and effectively delivered in an outpatient setting under local anaesthesia, even among higher-risk patients. The study demonstrates encouraging short-term symptom improvement, but the limited and selective long-term data preclude firm conclusions regarding durability or broader service impact. Larger, controlled studies with structured long-term follow-up are required to define the role of outpatient RFA within haemorrhoid care pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.